Answers are grounded in this paper and cite their sources.
Editorial comment highlights adverse events in renal cell carcinoma following pembrolizumab therapy, suggesting critical insights for practitioners.
Hajime Tanaka is an Editorial Board member of International Journal of Urology and an author of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
No takes yet. Share an insight, caveat, or question.
Hajime Tanaka (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: